Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3402535rdf:typepubmed:Citationlld:pubmed
pubmed-article:3402535lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:3402535lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:3402535lifeskim:mentionsumls-concept:C0032718lld:lifeskim
pubmed-article:3402535lifeskim:mentionsumls-concept:C0015772lld:lifeskim
pubmed-article:3402535lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:3402535lifeskim:mentionsumls-concept:C0243127lld:lifeskim
pubmed-article:3402535lifeskim:mentionsumls-concept:C1442080lld:lifeskim
pubmed-article:3402535lifeskim:mentionsumls-concept:C0443331lld:lifeskim
pubmed-article:3402535pubmed:issue1-2lld:pubmed
pubmed-article:3402535pubmed:dateCreated1988-9-16lld:pubmed
pubmed-article:3402535pubmed:abstractTextThe effects of the vasodilating dihydropyridine, felodipine, on tissue concentrations of high-energy phosphates and on oxygen consumption and lactate production in the smooth muscle of the rat portal vein were investigated. Felodipine (100 nM) caused a gradual decrease in the amplitude of the spontaneous phasic contractions in a calcium-containing medium. The mean active force was reduced by about 80% within 15 min. The inhibition of force was associated with reductions in both oxygen consumption and lactate production. No effects of felodipine could be observed in a calcium-free solution. The metabolic rates and force during felodipine inhibition approached those recorded in the calcium-free media. Felodipine (30 nM) did not alter the tissue levels of ATP, ADP, AMP and phosphocreatine. Relaxation by felodipine is thus associated with a decreased energy demand for contraction and, possibly, ionic translocation. The reduced ATP hydrolysis is compensated for by the regeneration of metabolic ATP, thus keeping the cellular levels of high-energy phosphates constant.lld:pubmed
pubmed-article:3402535pubmed:languageenglld:pubmed
pubmed-article:3402535pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3402535pubmed:citationSubsetIMlld:pubmed
pubmed-article:3402535pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3402535pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3402535pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3402535pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3402535pubmed:statusMEDLINElld:pubmed
pubmed-article:3402535pubmed:monthMaylld:pubmed
pubmed-article:3402535pubmed:issn0014-2999lld:pubmed
pubmed-article:3402535pubmed:authorpubmed-author:ArnerAAlld:pubmed
pubmed-article:3402535pubmed:authorpubmed-author:BoströmS LSLlld:pubmed
pubmed-article:3402535pubmed:issnTypePrintlld:pubmed
pubmed-article:3402535pubmed:day20lld:pubmed
pubmed-article:3402535pubmed:volume150lld:pubmed
pubmed-article:3402535pubmed:ownerNLMlld:pubmed
pubmed-article:3402535pubmed:authorsCompleteYlld:pubmed
pubmed-article:3402535pubmed:pagination15-22lld:pubmed
pubmed-article:3402535pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3402535pubmed:meshHeadingpubmed-meshheading:3402535-...lld:pubmed
pubmed-article:3402535pubmed:meshHeadingpubmed-meshheading:3402535-...lld:pubmed
pubmed-article:3402535pubmed:meshHeadingpubmed-meshheading:3402535-...lld:pubmed
pubmed-article:3402535pubmed:meshHeadingpubmed-meshheading:3402535-...lld:pubmed
pubmed-article:3402535pubmed:meshHeadingpubmed-meshheading:3402535-...lld:pubmed
pubmed-article:3402535pubmed:meshHeadingpubmed-meshheading:3402535-...lld:pubmed
pubmed-article:3402535pubmed:meshHeadingpubmed-meshheading:3402535-...lld:pubmed
pubmed-article:3402535pubmed:meshHeadingpubmed-meshheading:3402535-...lld:pubmed
pubmed-article:3402535pubmed:meshHeadingpubmed-meshheading:3402535-...lld:pubmed
pubmed-article:3402535pubmed:meshHeadingpubmed-meshheading:3402535-...lld:pubmed
pubmed-article:3402535pubmed:meshHeadingpubmed-meshheading:3402535-...lld:pubmed
pubmed-article:3402535pubmed:meshHeadingpubmed-meshheading:3402535-...lld:pubmed
pubmed-article:3402535pubmed:meshHeadingpubmed-meshheading:3402535-...lld:pubmed
pubmed-article:3402535pubmed:year1988lld:pubmed
pubmed-article:3402535pubmed:articleTitleEffects of felodipine on energy turnover in the rat portal vein.lld:pubmed
pubmed-article:3402535pubmed:affiliationDepartment of Physiology and Biophysics, University of Lund, Sweden.lld:pubmed
pubmed-article:3402535pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3402535pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed